Zhitong Finance App News, Huadong Pharmaceutical (000963.SZ) announced that Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“China-US Huadong”), a wholly-owned subsidiary of the company, received two “Drug Clinical Trial Approval Notices” approved and issued by the National Drug Administration (NMPA), and 0.15% rofloxate cream (ZORYVE®) and 0.3% rofloxate cream (ZORYVE®) clinical trial applications declared by China and the US East China were approved.

Zhitongcaijing · 09/29 10:25
Zhitong Finance App News, Huadong Pharmaceutical (000963.SZ) announced that Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“China-US Huadong”), a wholly-owned subsidiary of the company, received two “Drug Clinical Trial Approval Notices” approved and issued by the National Drug Administration (NMPA), and 0.15% rofloxate cream (ZORYVE®) and 0.3% rofloxate cream (ZORYVE®) clinical trial applications declared by China and the US East China were approved.